Fig. 1.

ARH3 loss impacts cancer cell response to PARPi and PARGi. (A) Schematic representation of the main gene mutation profile of the cell lines employed in this study. (B) Representative western blotting analysis of ARH3 protein levels in total cell lysates extracted from control and independent clones of ARH3 KO U2OS, COV362, OVCAR8, and PEO1 cell lines. α-tubulin served as loading controls. (C-F) Survival fraction of cell colony formation assay performed in control and ARH3 KO cells. U2OS, COV362, OVCAR8, and PEO1 cells were treated with olaparib and PARGi used at the indicated concentrations. Experiments were performed in biological and technical triplicates.